Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 Effect of the inhibition of vascular tissue factor activity by recombinant TF pathway inhibitor (rTFPI) on the thrombogenicity of human atherosclerotic lesions (30). (A) Representative immunophotograph of control. (B) rTFPI-treated human lipid-rich atherosclerotic lesions. rTFPI was associated with a significant reduction of acute thrombus formation, both platelet and fibrin(ogen) thrombus component, in human lipid-rich plaques. Reproduced with permission from Lippincott, Williams and Wilkins.
